How should failed BACE1 inhibitor trials (verubecestat, atabecestat) be represented as confidence drift in the evidence graph?

Evidence span

How should failed BACE1 inhibitor trials (verubecestat, atabecestat) be represented as confidence drift in the evidence graph?

Method & conditions

Evidence type

observational

Method

manual state transition

Conditions

Scope imported from broad Alzheimer's Therapeutics frontier; curator review required.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required